NCT06183489
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06183489
Title Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)
Acronym ERASMM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network B.V.
Indications
Therapies
Age Groups: senior | adult
Covered Countries NOR | NLD | ITA | FRA

Facility Status City State Zip Country Details
CHD Vendée La Roche-sur-Yon France Details
CHU Saint Eloi Département d'Hématologie Clinique Montpellier France Details
C.H.U. de Nantes Nantes France Details
CHU Poitiers - Pôle régional de Cancérologie Poitiers France Details
CHRU Hôpital Bretonneau Tours France Details
AOU Consorziale Policlinico di Bari Bari Italy Details
A.O. Papa Giovanni XXIII Bergamo Italy Details
A.O.U. Careggi Florence Italy Details
A.O.U. Policlinico S. Martino - Ematologia Genova Italy Details
Meldola-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) Meldola Italy Details
A.O.U. Maggiore della Carità Novara Novara Italy Details
A.O. di Padova Padova Italy Details
Fondazione IRCCS Policlinico S. Matteo Pavia Italy Details
Ospedale Santo Spirito Ospedale -Azienda Sanitaria Locale Di Pescara Roma Italy Details
Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale Udine Italy Details
St. Antonius Ziekenhuis Nieuwegein Netherlands Details
Erasmus MC Rotterdam Netherlands Details
Oslo Myeloma Center Oslo 0450 Norway Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field